Biomarker profiles in heart failure patients with obesity being treated with empagliflozin
Abstract
Heart failure (HF) and obesity are closely linked conditions that affect millions of people worldwide. Heart failure is a long-term condition in which the heart cannot pump blood around the body as well as it should. Obesity can worsen symptoms of heart failure, increase inflammation in the body, and contribute to poorer health outcomes. However, the biological pathways connecting obesity and heart failure are not fully understood. A biological pathway is a linked series of molecular actions or chemical reactions inside a cell. It allows cells to perform essential tasks. This research project aims to use stored blood samples from the EMPEROR-Preserved and EMPEROR-Reduced clinical trials to look for signs in the blood (called biomarkers) linked to obesity and metabolism (how the body processes energy). These trials evaluated empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF - where the heart pumps out a normal amount of blood but is too stiff to fill properly between beats) and reduced ejection fraction (HFrEF - where the heart muscle is weak and cannot pump enough blood with each beat), respectively. Empagliflozin helps the body get rid of extra sugar and salt through the urine by making the kidneys remove them instead of sending them back into the blood. This can lower blood sugar, reduce fluid build-up, and ease strain on the heart and kidneys. A subset of participants in these studies provided blood samples for future research. The…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.